Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
TRAF4
REST API REST API
Homo sapiens
TRAF4 is differentially expressed in 329 experiments: 125 organism parts: liver, mammary gland, ... (123 more);, 219 disease states: normal, acute myeloid leukemia, ... (217 more);, 110 cell types 437 cell lines 58 compound treatments and 79 other conditions.
Synonyms MLN62, RNF83, CART1
Orthologs TRAF4 (Gallus gallus)   Traf4 (Rattus norvegicus)   Traf4 (Mus musculus)   TRAF4 (Bos taurus)   Q1RLF0_CIOIN (Ciona intestinalis)   traf4a (Danio rerio)   Traf4 (Drosophila melanogaster)   traf4 (Xenopus laevis)   TRAF4 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term WW domain binding, plasma membrane, DNA binding, protein binding, cytoskeleton, cytoplasm, tight junction, metal ion binding, cell junction, positive regulation of JNK cascade, positive regulation of protein kinase activity, multicellular organismal development, protein kinase binding, nucleus, ubiquitin-protein ligase activity, receptor activity, perinuclear region of cytoplasm, signal transduction, zinc ion binding, regulation of apoptosis, respiratory gaseous exchange, positive regulation of protein homodimerization activity, respiratory tube development
InterPro Term MATH, Znf_RING, Znf_TRAF, Znf_C3HC4_RING-type, TNF_rcpt--assoc_TRAF
UniProt Accession Q2KJU3, Q2KJU6, C9JJ10, B4DUU9, Q9BUZ4
Search EB-eye ENSG00000076604
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, ... (28 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-2450, ... (42 experiments)

Factor Value U/D Experiments
HL-60
4
E-GEOD-5258, E-MTAB-37, E-GEOD-96, E-GEOD-24147
MCF-7
4
E-GEOD-5823, E-GEOD-19639, E-GEOD-20081, E-GEOD-3529
BT-474
2
E-GEOD-5823, E-GEOD-3529
KG1
2
E-MTAB-37, E-GEOD-24147
LNCaP
2
E-GEOD-14990, E-GEOD-14464
MDAMB453
2
E-MTAB-37, E-MTAB-62
431 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, ... (53 experiments)

Factor Value U/D Experiments
monocyte
1
4
E-GEOD-11755, E-MEXP-583, E-GEOD-7307, E-GEOD-22373, E-GEOD-8286 ... (5 experiments)
CD8+ T cell
2
E-AFMX-5, E-TABM-145
CD56+ NK cells
2
E-AFMX-5, E-TABM-145
centroblast
2
E-GEOD-15271, E-TABM-702
human foreskin fibroblast
2
E-GEOD-18265, E-GEOD-18147
1
2
E-TABM-145, E-TABM-130
104 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-TABM-15, ... (67 experiments)

Factor Value U/D Experiments
glioblastoma
4
E-GEOD-4290, E-MTAB-37, E-GEOD-6014, E-MEXP-567
lung adenocarcinoma
4
E-GEOD-2514, E-MEXP-231, E-MTAB-62, E-MTAB-37
prostate carcinoma
1
3
E-MTAB-62, E-MEXP-2034, E-GEOD-96, E-MEXP-1327
colorectal carcinoma
2
E-GEOD-4045, E-GEOD-23878
adenocarcinoma
2
E-MTAB-37, E-MTAB-62
cervical carcinoma
1
2
E-MTAB-62, E-MTAB-37, E-GEOD-5823
213 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-5741, E-TABM-782, E-GEOD-3720, E-TABM-868, ... (32 experiments)

Factor Value U/D Experiments
none
2
6
E-MEXP-1601, E-TABM-782, E-MEXP-1958, E-GEOD-20719, E-GEOD-412, ... (8 experiments)
lipopolysaccharide
3
E-GEOD-3720, E-MEXP-1958, E-TABM-868
CNOT7+CNOT8
1
1
E-MEXP-2218
HMB-PP (phosphoantigen)
1
E-MEXP-1601
control for EGF
1
E-GEOD-6462
Cxcl12
1
E-GEOD-7307
52 more value(s).


Age at diagnosis

studied in E-GEOD-3494, E-GEOD-4922

Factor Value U/D Experiments
29 years
1
1
E-GEOD-4922
29
2
1
E-GEOD-3494
50
1
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37, E-GEOD-14359, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd4
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-1563, E-GEOD-21589, ... (7 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, ... (7 experiments)

Dfs follow up
studied in E-GEOD-22541

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-GEOD-3325, E-GEOD-22541, E-TABM-147, ... (6 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Erbb2
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, ... (10 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-2466, E-GEOD-17476, E-TABM-868, E-TABM-601, ... (13 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-MEXP-2657, E-GEOD-20540, E-GEOD-10315, E-GEOD-837, ... (15 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-302, E-GEOD-21653, E-GEOD-20559, E-TABM-276 ... (5 experiments)

immunoprecipitated protein
studied in E-GEOD-21918

Individual
studied in E-MTAB-197, E-GEOD-5764, E-TABM-740, E-GEOD-2466, E-GEOD-1926, ... (31 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, ... (8 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977, E-TABM-321

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-1493, E-GEOD-22309, E-GEOD-21750, E-GEOD-1460

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, ... (9 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

Sex
studied in E-GEOD-19069, E-GEOD-2466, E-GEOD-22541, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276, E-GEOD-2748

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19815, E-GEOD-15799, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-TABM-43, E-GEOD-1561, E-GEOD-6532 ... (5 experiments)

Tumor size
studied in E-GEOD-8167, E-GEOD-3494

Vehicle
studied in E-GEOD-5258

Processing time: 0.434 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM